APOE2 enhances neuroprotection against Alzheimer’s disease through multiple molecular mechanisms
Abstract
The common APOE2 gene variant is neuroprotective against Alzheimer's disease (AD) and reduces risk by nearly 50%. However, the mechanisms by which APOE2 confers neuroprotection are largely unknown. Here we showed that ApoE protein abundance in human postmortem cortex follows an isoform-dependent pattern (E2>E3>E4). We also identified a unique downstream transcriptional profile determined by microarray and characterized by downregulation of long-term potentiation (LTP) related transcripts and upregulation of extracellular matrix (ECM)/integrin-related transcripts in E2 cases and corroborated this finding at the protein level by demonstrating increases in ECM collagens and laminins. In vivo studies of healthy older individuals demonstrated a unique and advantageous biomarker signature in E2 carriers. APOE2 also reduced the risk of mild cognitive impairment to AD conversion by half. Our findings suggest that ApoE2 protein abundance, coupled with its inability to bind to LDLRs, may act to increase amyloid-beta (Ab) clearance. In addition, increased ECM and reduced LTP-related expression results in diminished activity-dependent Ab secretion and/or excitotoxicity, and thus also promotes neuroprotection.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The APOE2hAβ LTP finding is consistent with observations reported in APOE2-carrying mice but appears paradoxical given APOE2's typical association with neuroprotection in AD.
“This finding is consistent with observations reported in APOE2-carrying mice [82], but appears paradoxical given APOE2’s typical association with neuroprotection in AD [83, 84].”
APOE2 markedly delays the age of onset of Alzheimer's disease, even in the presence of the APOE4 allele.
“and markedly delaying the age of onset, even in the presence of the APOE4 allele.12,13”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [12]
APOE2 is a protective allele, reducing Alzheimer's disease risk by approximately 50% (1.8-fold decreased risk).
“In contrast, APOE2 is a protective allele, reducing AD risk by approximately 50% (1.8-fold decreased risk)”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [12]
Individuals who are APOE4 homozygotes have a markedly increased risk of developing AD.
“Individuals who are APOE4 homozygotes have a markedly increased risk of developing AD.”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [12]
APOE2 homozygotes are protected from late-onset AD.
“APOE2 homozygotes are protected from late-onset AD and, compared to E4 homozygotes, APOE2/E4 heterozygotes have a markedly reduced risk of developing AD.6,12,13”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [12]
Compared to E4 homozygotes, APOE2/E4 heterozygotes have a markedly reduced risk of developing AD.
“APOE2 homozygotes are protected from late-onset AD and, compared to E4 homozygotes, APOE2/E4 heterozygotes have a markedly reduced risk of developing AD.6,12,13”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [12]
Converting an APOE4 homozygote to an E4/E2 heterozygote would markedly decrease the risk for developing early-onset AD compared with E4 homozygotes.
“From epidemiologic studies, this would markedly decrease the risk for developing early-onset AD compared to E4 homozygotes.”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [12]
CypA mRNA is increased in Alzheimer's disease brains.
“CypA mRNA is also increased in AD brains (118).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [118]
APOE2 expression leads to increased APOE levels in mouse models and human brain, which can influence amyloid pathology.
“It has also been shown that APOE2 expression leads to increased APOE levels in mouse models and human brain (Riddell et al, 2008; Bales et al, 2009; Conejero-Goldberg et al, 2014), which can influence amyloid pathology.”
From APOE from astrocytes restores Alzheimer’s Aβ-pathology and DAM-like responses in APOE deficient microglia (2024) · cites this paper as Conejero-Goldberg et al, 2014
Cites
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · see citing works
Buckner, R. L., Sepulcre, J., Talukdar, T., Krienen, F. M., Liu, H., Hedden, T., Andrews-Hanna, J. R., Sperling, R. A., & Johnson, K. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5062-08.2009 · Cited by 2,862 · see citing works
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · see citing works
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · see citing works
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · see citing works
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · see citing works
Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.028 · Cited by 1,265 · see citing works
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,227 · see citing works
Endothelial Extracellular Matrix
Davis, G. E., & Senger, D. R. (2005) · Circulation Research · doi:10.1161/01.res.0000191547.64391.e3 · Cited by 1,225 · see citing works
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168 · see citing works
Linking lipids to Alzheimer's disease: cholesterol and beyond
Di Paolo, G., & Kim, T.-W. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3012 · Cited by 972 · see citing works
Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600549103 · Cited by 912 · see citing works
Neuronal activity regulates the regional vulnerability to amyloid-β deposition
Bero, A. W., Yan, P., Roh, J. H., Cirrito, J. R., Stewart, F. R., Raichle, M. E., Lee, J.-M., & Holtzman, D. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2801 · Cited by 880 · see citing works
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876 · see citing works
<i>APOE</i> predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830 · see citing works
Association of apolipoprotein E genotypes with lipid levels and coronary risk
Bennet, A. M., Di Angelantonio, E., Ye, Z., Wensley, F., Dahlin, A., Ahlbom, A., Keavney, B., Collins, R., Wiman, B., de Faire, U., et al. (2007) · JAMA · doi:10.1001/jama.298.11.1300 · Cited by 794 · see citing works
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782 · see citing works
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · see citing works
Suberbielle, E., Sanchez, P. E., Kravitz, A. V., Wang, X., Ho, K., Eilertson, K., Devidze, N., Kreitzer, A. C., & Mucke, L. (2013) · Nature Neuroscience · doi:10.1038/nn.3356 · Cited by 487 · see citing works
Mahley, R. W., Huang, Y., & Rall, S. C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32417-2 · Cited by 447 · see citing works
Apolipoprotein e sets the stage: response to injury triggers neuropathology
Mahley, R. W., & Huang, Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.11.020 · Cited by 412 · see citing works
The perineuronal net and the control of CNS plasticity
Wang, D., & Fawcett, J. (2012) · Cell and Tissue Research · doi:10.1007/s00441-012-1375-y · Cited by 373 · see citing works
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
Riddell, D. R., Zhou, H., Atchison, K., Warwick, H. K., Atkinson, P. J., Jefferson, J., Xu, L., Aschmies, S., Kirksey, Y., Hu, Y., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1972-08.2008 · Cited by 342 · see citing works
Harris, F. M., Brecht, W. J., Xu, Q., Tesseur, I., Kekonius, L., Wyss-Coray, T., Fish, J. D., Masliah, E., Hopkins, P. C., Scearce-Levie, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1434398100 · Cited by 342 · see citing works
Gomar, J. J. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.96 · Cited by 340 · see citing works
Self-citationReymann, K. G., & Frey, J. U. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.07.026 · Cited by 331 · see citing works
Human<i>APOE</i>Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice
Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J. C., Sullivan, P. M., & Paul, S. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0887-09.2009 · Cited by 274 · see citing works
Cerebrovascular Effects of Apolipoprotein E: Implications for Alzheimer Disease
Zlokovic, B. V. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2152 · Cited by 263 · see citing works
Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease
Soares, H. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1070 · Cited by 218 · see citing works
Gerdes, L. U., Jeune, B., Andersen‐Ranberg, K., Nybo, H., & Vaupel, J. W. (2000) · Genetic Epidemiology · doi:10.1002/1098-2272(200010)19:3 · Cited by 204 · see citing works
Integrin Requirement for Hippocampal Synaptic Plasticity and Spatial Memory
Chan, C.-S., Weeber, E. J., Kurup, S., Sweatt, J. D., & Davis, R. L. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-18-07107.2003 · Cited by 202 · see citing works
Palop, J. J., & Mucke, L. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8097-7 · Cited by 177 · see citing works
Sudlow, C. L. M., Martínez-González, N. A., Kim, J., & Clark, C. (2005) · Stroke · doi:10.1161/01.str.0000199065.12908.62 · Cited by 167 · see citing works
The apolipoprotein E varepsilon2 allele and decline in episodic memory
Wilson, R. S. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.6.672 · Cited by 161 · see citing works
APOE-ε2 allele associated with higher prevalence of sporadic Parkinson disease
Huang, X., Chen, P., & Poole, C. (2004) · Neurology · doi:10.1212/01.wnl.0000130159.28215.6a · Cited by 158 · see citing works
de Vivo, L., Landi, S., Panniello, M., Baroncelli, L., Chierzi, S., Mariotti, L., Spolidoro, M., Pizzorusso, T., Maffei, L., & Ratto, G. M. (2013) · Nature Communications · doi:10.1038/ncomms2491 · Cited by 148 · see citing works
Aleshkov, S., Abraham, C. R., & Zannis, V. I. (1997) · Biochemistry · doi:10.1021/bi9626362 · Cited by 138 · see citing works
ApoE isoform affects LTP in human targeted replacement mice
Trommer, B. L., Shah, C., Yun, S. H., Gamkrelidze, G., Pasternak, E. S., Ye, G. L., Sotak, M., Sullivan, P. M., Pasternak, J. F., & LaDu, M. J. (2004) · NeuroReport · doi:10.1097/00001756-200412030-00020 · Cited by 124 · see citing works
Tolar, M., Marques, M. A., Harmony, J. A. K., & Crutcher, K. A. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-15-05678.1997 · Cited by 115 · see citing works
Yang, D., Smith, J. D., Zhou, Z., Gandy, S. E., & Martins, R. N. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68020721.x · Cited by 111 · see citing works
Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis
Verpillat, P., Camuzat, A., Hannequin, D., Thomas-Antérion, C., Puel, M., Belliard, S., Dubois, B., Didic, M., Lacomblez, L., Moreaud, O., et al. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200820 · Cited by 100 · see citing works
Togo, T., Cookson, N., & Dickson, D. W. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00421.x · Cited by 100 · see citing works
Hippocampal atrophy rates and CSF biomarkers in elderly <i>APOE</i> 2 normal subjects
Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran-Sacrey, D., Raptentsetsang, S. T., Jack, C. R., Aisen, P. S., Petersen, R. C., Weiner, M. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4d1 · Cited by 94 · see citing works
Lendvai, D., Morawski, M., Négyessy, L., Gáti, G., Jäger, C., Baksa, G., Glasz, T., Attems, J., Tanila, H., Arendt, T., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-012-1042-0 · Cited by 93 · see citing works
The association of apolipoprotein E polymorphism with memory: a population based study
Helkala, E., Koivisto, K. J., Hänninen, T., Vanhanen, M., Kervinen, K., Kuusisto, J., Mykkänen, L. M., Kesäniemi, Y. A., Laakso, M., & Riekkinen, P. J. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11575-h · Cited by 89 · see citing works
APOE Genotype, Lipids, and Coronary Heart Disease Risk
Ward, H. A., Mitrou, P. N., Bowman, R., Luben, R., Wareham, N. J., Khaw, K., & Bingham, S. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.234 · Cited by 84 · see citing works
Jones, P. B., Adams, K. W., Rozkalne, A., Spires-Jones, T. L., Hshieh, T. T., Hashimoto, T., von Armin, C. A. F., Mielke, M., Bacskai, B. J., & Hyman, B. T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014586 · Cited by 84 · see citing works
Deary, I. J., Whiteman, M. C., Pattie, A., Starr, J. M., Hayward, C., Wright, A. F., Visscher, P. M., Tynan, M. C., & Whalley, L. J. (2004) · Psychology and Aging · doi:10.1037/0882-7974.19.2.367 · Cited by 76 · see citing works
Drenos, F., & Kirkwood, T. B. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010022 · Cited by 59 · see citing works
Conejero-Goldberg, C., Hyde, T., Chen, S., Dreses-Werringloer, U., Herman, M., Kleinman, J., Davies, P., & Goldberg, T. E. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.57 · Cited by 54 · see citing works
Self-citationArgyrophilic grain disease is associated with apolipoprotein E ε2 allele
Ghebremedhin, E., Schultz, C., Botez, G., Rüb, U., Sassin, I., Braak, E., & Braak, H. (1998) · Acta Neuropathologica · doi:10.1007/s004010050886 · Cited by 50 · see citing works
Xu, P., Schmechel, D. E., Qiu, H.-L., Herbstreith, M. H., Rothrock‐Christian, T., Eyster, M. V., Roses, A. D., & Gilbert, J. R. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0213 · Cited by 46 · see citing works
Function and Comorbidities of Apolipoprotein E in Alzheimer′s Disease
Leduc, V., Domenger, D., Beaumont, L. D., Lalonde, D., Jasmin, S. B., & Poirier, J. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/974361 · Cited by 45 · see citing works
Role of apoE/Aβ interactions in Alzheimer's disease: insights from transgenic mouse models
Brendza, R. P., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001006 · Cited by 30 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076 · see citing works
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,294 · see citing works
Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672 · see citing works
Halliday, M. R., Rege, S. V., Ma, Q., Zhao, Z., Miller, C. A., Winkler, E. A., & Zlokovic, B. V. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.44 · Cited by 649 · see citing works
Liu, L., MacKenzie, K. R., Putluri, N., Maletić-Savatić, M., & Bellen, H. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.024 · Cited by 556 · see citing works
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00413-4 · Cited by 306 · see citing works
The Pericyte: A Forgotten Cell Type with Important Implications for A lzheimer's Disease?
Winkler, E. A., Sagare, A. P., & Zloković, B. V. (2014) · Brain Pathology · doi:10.1111/bpa.12152 · Cited by 275 · see citing works
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L. R., Daley, D. A., Black, K. L., & Koronyo‐Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275 · see citing works
Dysregulation of lipids in Alzheimer’s disease and their role as potential biomarkers
Wong, M. W., Braidy, N., Poljak, A., Pickford, R., Thambisetty, M., & Sachdev, P. S. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.008 · Cited by 223 · see citing works
Ancestral origin of ApoE ε4 Alzheimer disease risk in Puerto Rican and African American populations
Rajabli, F., Feliciano, B. E., Celis, K., Hamilton-Nelson, K. L., Whitehead, P. L., Adams, L. D., Bussies, P. L., Manrique, C. P., Rodriguez, A., Rodriguez, V., et al. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007791 · Cited by 206 · see citing works
Gharbi‐Meliani, A., Dugravot, A., Sabia, S., Régy, M., Fayossé, A., Schnitzler, A., Mika Kivimaki, B., Singh‐Manoux, A., & Dumurgier, J. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00740-0 · Cited by 179 · see citing works
Moulton, M. J., Barish, S., Ralhan, I., Chang, J., Goodman, L. D., Harland, J. G., Marcogliese, P. C., Johansson, J. O., Ioannou, M. S., & Bellen, H. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112095118 · Cited by 180 · see citing works
AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease
Rosenberg, J. B., Kaplitt, M. G., De, B. P., Chen, A., Flagiello, T., Salami, C., Pey, E., Zhao, L., Ricart Arbona, R. J., Monette, S., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.231 · Cited by 169 · see citing works
Genetics ignite focus on microglial inflammation in Alzheimer’s disease
Malik, M., Parikh, I., Vasquez, J. B., Smith, C., Tai, L., Bu, G., LaDu, M. J., Fardo, D. W., Rebeck, G. W., & Estus, S. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0048-1 · Cited by 161 · see citing works
Arora, S., Layek, B., & Singh, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00461 · Cited by 149 · see citing works
Peters, D. G., Connor, J. R., & Meadowcroft, M. D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.007 · Cited by 145 · see citing works
Pathological changes within the cerebral vasculature in Alzheimer’s disease: New perspectives
Fisher, R. A., Miners, J. S., & Love, S. (2022) · Brain Pathology · doi:10.1111/bpa.13061 · Cited by 127 · see citing works
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124 · see citing works
Kipanyula, M. J., Kimaro, W. H., & Etet, P. F. S. (2016) · Journal of Aging Research · doi:10.1155/2016/5081021 · Cited by 112 · see citing works
Functional Roles of the Interaction of APP and Lipoprotein Receptors
Pohlkamp, T., Wasser, C. R., & Herz, J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00054 · Cited by 92 · see citing works
Lipoproteins in the Central Nervous System: From Biology to Pathobiology
Raulin, A.-C., Martens, Y. A., & Bu, G. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-104801 · Cited by 89 · see citing works
Aβ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease
Condello, C., & Stöhr, J. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.014 · Cited by 87 · see citing works
Association of APOE e2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies
Goldberg, T. E., Huey, E. D., & Devanand, D. P. (2020) · Nature Communications · doi:10.1038/s41467-020-18198-x · Cited by 82 · see citing works
Self-citationAPOE2 is associated with longevity independent of Alzheimer’s disease
Shinohara, M., Kanekiyo, T., Tachibana, M., Kurti, A., Shinohara, M., Fu, Y., Zhao, J., Han, X., Sullivan, P. M., Rebeck, G. W., et al. (2020) · eLife · doi:10.7554/elife.62199 · Cited by 82 · see citing works
ApoE-2 Brain-Targeted Gene Therapy Through Transferrin and Penetratin Tagged Liposomal Nanoparticles
Rodrigues, B. D. S., Kanekiyo, T., & Singh, J. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2691-7 · Cited by 81 · see citing works
Lewandowski, C. T., Maldonado Weng, J., & LaDu, M. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104811 · Cited by 72 · see citing works
Lipids in Amyloid-β Processing, Aggregation, and Toxicity
Morgado, I., & Garvey, M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-17344-3_3 · Cited by 69 · see citing works
Extracellular Matrix Proteins Involved in Alzheimer's Disease
Ma, J., Ma, C., Li, J., Sun, Y., Ye, F., Liu, K., & Zhang, H. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000782 · Cited by 67 · see citing works
Murine Gut Microbiome Association With APOE Alleles
Parikh, I. J., Estus, J. L., Zajac, D. J., Malik, M., Weng, J. M., Tai, L. M., Chlipala, G. E., LaDu, M. J., Green, S. J., & Estus, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00200 · Cited by 63 · see citing works
Konishi, K., Bhat, V., Banner, H., Poirier, J., Joober, R., & Bohbot, V. D. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00349 · Cited by 63 · see citing works
Panitch, R., Hu, J., Chung, J., Zhu, C., Meng, G., Xia, W., Bennett, D. A., Lunetta, K. L., Ikezu, T., Au, R., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01266-z · Cited by 58 · see citing works
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease
Xia, Z., Prescott, E. E., Urbanek, A., Wareing, H. E., King, M. C., Olerinyova, A., Dakin, H., Leah, T., Barnes, K. A., Matuszyk, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49028-z · Cited by 67 · see citing works
Molecular Insight into the Therapeutic Promise of TargetingAPOE4for Alzheimer’s Disease
Mamun, A. A., Uddin, M. S., Bashar, M. F. B., Zaman, S., Begum, Y., Bulbul, I. J., Islam, M. S., Sarwar, M. S., Mathew, B., Amran, M. S., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5086250 · Cited by 53 · see citing works
Dowell, N. G., Evans, S., Tofts, P. S., King, S. L., Tabet, N., & Rusted, J. M. (2016) · NMR in Biomedicine · doi:10.1002/nbm.3502 · Cited by 50 · see citing works
Plasma apolipoproteins and physical and cognitive health in very old individuals
Muenchhoff, J., Song, F., Poljak, A., Crawford, J. D., Mather, K. A., Kochan, N. A., Yang, Z., Trollor, J. N., Reppermund, S., Maston, K., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.02.017 · Cited by 50 · see citing works
Impact of late-onset Alzheimer’s genetic risk factors on beta-amyloid endocytic production
Almeida, C. G., Mirfakhar, F. S., Perdigão, C., & Burrinha, T. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2825-9 · Cited by 48 · see citing works
APOE Genotype and Nonrespiratory Sleep Parameters in Cognitively Intact Older Adults
Spira, A. P., An, Y., Peng, Y., Wu, M. N., Simonsick, E. M., Ferrucci, L., & Resnick, S. M. (2017) · SLEEP · doi:10.1093/sleep/zsx076 · Cited by 48 · see citing works
Race, APOE genotypes, and cognitive decline among middle-aged urban adults
Beydoun, M. A., Weiss, J., Beydoun, H. A., Hossain, S. A., Maldonado, A. I., Shen, B., Evans, M. K., & Zonderman, A. B. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00855-y · Cited by 48 · see citing works
Pirhaghi, M., Mamashli, F., Moosavi-Movahedi, F., Arghavani, P., Amiri, A., Davaeil, B., Mohammad-Zaheri, M., Mousavi-Jarrahi, Z., Sharma, D., Langel, Ü., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01167 · Cited by 47 · see citing works
Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load
Grothe, M. J., Villeneuve, S., Dyrba, M., David Bartrés-faz, A., Wirth, M., Initiative, A. D. N., Initiative, A. D. N., Weiner, M. W., Aisen, P., Weiner, M. W., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003585 · Cited by 47 · see citing works
APOE genetics influence murine gut microbiome
Zajac, D. J., Green, S. J., Johnson, L. A., & Estus, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-05763-1 · Cited by 41 · see citing works
Schmid, B., Prehn, K. R., Nimsanor, N., Garcia, B. I. A., Poulsen, U., Jørring, I., Rasmussen, M. A., Clausen, C., Mau-Holzmann, U. A., Ramakrishna, S., et al. (2019) · Stem Cell Research · doi:10.1016/j.scr.2018.11.010 · Cited by 40 · see citing works
Apolipoprotein E Genotype e2: Neuroprotection and Its Limits
Kim, H., Devanand, D. P., Carlson, S., & Goldberg, T. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.919712 · Cited by 36 · see citing works
Self-citationLim, Y. Y., Williamson, R., Laws, S. M., Villemagne, V. L., Bourgeat, P., Fowler, C. J., Rainey‐Smith, S. R., Salvado, O., Martins, R. N., Rowe, C. C., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170072 · Cited by 40 · see citing works
Dafnis, I., Argyri, L., Sagnou, M., Tzinia, A., Tsilibary, E. C., Stratikos, E., & Chroni, A. (2016) · Scientific Reports · doi:10.1038/srep30654 · Cited by 38 · see citing works
Genetic cartography of longevity in humans and mice: Current landscape and horizons
Hook, M., Roy, S., Williams, E. G., Sleiman, M. S. B., Mozhui, K., Nelson, J. F., Lu, L., Auwerx, J. H., & Williams, R. W. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.026 · Cited by 33 · see citing works
Preman, P., Moechars, D., Fertan, E., Wolfs, L., Serneels, L., Shah, D., Lamote, J., Poovathingal, S., Snellinx, A., Mancuso, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00162-7 · Cited by 32 · see citing works
Iacono, D., & Feltis, G. C. (2019) · Aging · doi:10.18632/aging.101757 · Cited by 32 · see citing works
Olfactory Dysfunction and Alzheimer’s Disease: A Review
McLaren, A., & Kawaja, M. D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231377 · Cited by 31 · see citing works
Genetics of frailty: A longevity perspective
Sathyan, S., & Verghese, J. (2020) · Translational research · doi:10.1016/j.trsl.2020.03.005 · Cited by 30 · see citing works
Zhang, Y., Gao, H., Zheng, W., & Xu, H. J. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105824 · Cited by 30 · see citing works
APOE effects on cognition from childhood to adolescence
Reynolds, C. A., Smolen, A., Corley, R. P., Muñoz, E., Friedman, N. P., Rhee, S. H., Stallings, M. C., DeFries, J. C., & Wadsworth, S. J. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.04.011 · Cited by 29 · see citing works
The proteinopenia hypothesis: Loss of Aβ42 and the onset of Alzheimer’s Disease
Espay, A. J., Herrup, K., Kepp, K. P., & Daly, T. P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102112 · Cited by 29 · see citing works
Wang, Y., Sun, Y., Luo, Y., Peng, D., Li, X., Yang, B., Wang, Q., & Kuang, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.700587 · Cited by 28 · see citing works
(2020) · Cambridge University Press eBooks · doi:10.1017/9781108695374 · Cited by 28 · see citing works
Culture in Mind – An Enactivist Account
Hutto, D. D., Gallagher, S., Ilundáin‐Agurruza, J., & Hipólito, I. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108695374.009 · Cited by 25 · see citing works
Wang, Z., Dai, Z., Shu, H., Liu, D., Guo, Q., He, Y., & Zhang, Z. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160724 · Cited by 26 · see citing works
Olofsson, J., Larsson, M. U., Roa, C., Wilson, D. A., & Laukka, E. J. (2019) · Behavior Genetics · doi:10.1007/s10519-019-09980-9 · Cited by 25 · see citing works
Blöndal, T., Gamba, C., Jagd, L. M., Su, L., Demirov, D. G., Guo, S., Johnston, C. M., Riising, E. M., Wu, X., Mikkelsen, M. J., et al. (2021) · Methods · doi:10.1016/j.ymeth.2021.02.003 · Cited by 24 · see citing works
Wijekoon, N., Gonawala, L., Ratnayake, P. D., Dissanayaka, P., Gunarathne, I., Amaratunga, D., Liyanage, R., Senanayaka, S., Wijesekara, S., Gunasekara, H. H., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18530 · Cited by 25 · see citing works
APOE4 is a Risk Factor and Potential Therapeutic Target for Alzheimer's Disease
Ayyubova, G. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230303114425 · Cited by 23 · see citing works
James, L. M., Dolan, S., Leuthold, A. C., Engdahl, B. E., Georgopoulos, A., & Georgopoulos, A. P. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.026 · Cited by 23 · see citing works
Gomar, J. J., Conejero‐Goldberg, C., Huey, E. D., Davies, P., & Goldberg, T. E. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.12.004 · Cited by 23 · see citing works
Self-citationDumuid, D., Mellow, M. L., Olds, T., Tregoweth, E., Greaves, D., Keage, H. A. D., & Smith, A. E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220181 · Cited by 23 · see citing works
Current viral-mediated gene transfer research for treatment of Alzheimer’s disease
Sasmita, A. O. (2018) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2018.1523521 · Cited by 23 · see citing works
Triebswetter, C., Kiely, M., Khattar, N., Ferrucci, L., Resnick, S. M., Spencer, R. G. S., & Bouhrara, M. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.118988 · Cited by 22 · see citing works
Novel approaches to increase synaptic resilience as potential treatments for Alzheimer’s disease
Pham, A. Q., & Dore, K. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.03.032 · Cited by 21 · see citing works
Lipoprotein Particles in Cerebrospinal Fluid
Tsujita, M., Melchior, J., & Yokoyama, S. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.318284 · Cited by 21 · see citing works
Dong, Y., Newman, M., Pederson, S., Barthelson, K., Hin, N., & Lardelli, M. T. (2021) · BMC Genomics · doi:10.1186/s12864-021-07509-1 · Cited by 21 · see citing works
The Association of Essential Metals with APOE Genotype in Alzheimer’s Disease
Leko, M. B., Jurasović, J., Perković, M. N., Španić, E., Sekovanić, A., Orct, T., Lukinović-Škudar, V., Baronica, K. B., Kiđemet‐Piskač, S., Vogrinc, Ž., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210158 · Cited by 21 · see citing works
Gendron, M., Mesquita, B., & Barrett, L. F. (2020) · Culture, Mind, and Brain · doi:10.1017/9781108695374.010 · Cited by 20 · see citing works
Impact of APOE genotype on prion-type propagation of tauopathy
Williams, T., Ruiz, A. J., Ruiz, A. M., Vo, Q., Tsering, W., Xu, G. M., McFarland, K. N., Giasson, B. I., Sullivan, P. M., Borchelt, D., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01359-y · Cited by 21 · see citing works
Shared Human Leukocyte Antigen (HLA) Coverage in dementia and Parkinson’s disease
James, L. M., & Georgopoulos, A. P. (2020) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2020/3.1275 · Cited by 19 · see citing works
Human apolipoprotein E glycosylation and sialylation: from structure to function
Moon, H.-J., Luo, Y., Chugh, D., & Zhao, L. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1399965 · Cited by 18 · see citing works
Calvo, N., McFall, G. P., Ramana, S., Galper, M., Fuller‐Thomson, E., Dixon, R. A., & Einstein, G. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240646 · Cited by 22 · see citing works
Possible positive effect of the APOE ε2 allele on cognition in early to mid-adult life
Sinclair, L. I., Pleydell-Pearce, C. W., & Day, I. N. M. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.10.008 · Cited by 18 · see citing works
Bumber, J. R., Rački, V., Mežnarić, S., Pelčić, G., & Mršić‐Pelčić, J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176047 · Cited by 17 · see citing works
Iacono, D., Zandi, P. P., Gross, M. D., Markesbery, W. R., Pletniková, O., Rudow, G. L., & Troncoso, J. C. (2015) · Oncotarget · doi:10.18632/oncotarget.4118 · Cited by 17 · see citing works
Keable, A., O’Neill, R., MacGregor Sharp, M., Gatherer, M., Yuen, H. M., Johnston, D. A., Weller, R. O., & Carare, R. O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124371 · Cited by 15 · see citing works
Smith, J. A., Zhao, W., Yu, M., Rumfelt, K. E., Moorjani, P., Ganna, A., Dey, A. B., Lee, J., & Kardia, S. L. R. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16735 · Cited by 14 · see citing works
Wang, S., & Xiao, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052213 · Cited by 15 · see citing works
Bown, C. W., Liu, D., Osborn, K. E., Gupta, D. K., Mendes, L. A., Pechman, K. R., Hohman, T. J., Wang, T. J., Gifford, K. A., & Jefferson, A. L. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011146 · Cited by 15 · see citing works
Culture, Mind, and Brain: Emerging Concepts, Models, and Applications
Kirmayer, L. J., Worthman, C. M., Kitayama, S., Lemelson, R., & Cummings, C. A. (2020) · Cited by 15 · see citing works
Margrett, J. A., Schofield, T. J., Martin, P., Poon, L. W., Masaki, K., Donlon, T. A., Kallianpur, K. J., & Willcox, B. J. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab327 · Cited by 15 · see citing works
Cognitive behavioral therapy (CBT) for preventing Alzheimer’s disease
Reid, L. D., Avens, F. E., & Walf, A. A. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.07.024 · Cited by 15 · see citing works
APP -Induced Patterned Neurodegeneration Is Exacerbated by APOE4 in Caenorhabditis elegans
Sae-Lee, W., Scott, L. L., Brose, L., Encarnacion, A. J., Shi, T., Kore, P., Oyibo, L. O., Ye, C., Rozmiarek, S. K., & Pierce-Shimomura, J. T. (2020) · G3 Genes Genomes Genetics · doi:10.1534/g3.120.401486 · Cited by 13 · see citing works
The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson's disease
Pierzchlińska, A., Białecka, M. A., Kurzawski, M., & Sławek, J. W. (2018) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2018.04.003 · Cited by 14 · see citing works
Dhillon, V. S., Deo, P., Chua, A., Thomas, P., & Fenech, M. F. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz203 · Cited by 14 · see citing works
Gao, H., Zheng, W., Li, C., & Xu, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111582 · Cited by 14 · see citing works
Vlad, C.-E., Burlacu, A., Florea, L., Artene, B., Bădărau, S., Covic, A. S., Ureche, C., Scripcariu, D. V., Foia, L. G., & Covic, A. C. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02170-w · Cited by 14 · see citing works
Yang, X., Yao, K., Zhang, M., Zhang, W., & Zu, H. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111321 · Cited by 12 · see citing works
APOE and Alzheimer's disease and related dementias risk among 12,221 Hispanics/Latinos
Barral, S., Yang, Z., Phillips, N., Barber, R. C., Brickman, A. M., Honig, L. S., Cieza, B., Reyes‐Dumeyer, D., Mayeux, R. P., Rajabli, F., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70138 · Cited by 13 · see citing works
Chen, H., Zhao, S., Jian, Q., Yan, Y., Wang, S., Zhang, X., & Ji, Y. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-08921-4 · Cited by 13 · see citing works
Pancholi, B., Choudhary, M. K., Kumar, M., Babu, R., Vora, L. K., Khatri, D. K., & Garabadu, D. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106816 · Cited by 12 · see citing works
Cerebrovascular Disease and Cognitive Outcome in Patients with Cardiac Disease
Johansen, M. C., & Gottesman, R. F. (2021) · Seminars in Neurology · doi:10.1055/s-0041-1726330 · Cited by 12 · see citing works
Lipids in the Treatment of Neurodegenerative Diseases
Lange, K. W. (2020) · Wiley eBooks · doi:10.1002/047167849x.bio118 · Cited by 12 · see citing works
Mass Spectrometry-Based Analysis of Lipid Involvement in Alzheimer’s Disease Pathology—A Review
Kelley, A. R. (2022) · Metabolites · doi:10.3390/metabo12060510 · Cited by 10 · see citing works
McFall, G. P., Bäckman, L., & Dixon, R. A. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190315094452 · Cited by 11 · see citing works
Yesiltepe, M., Yin, T., Tambini, M., Bao, H., Pan, M., d’Abramo, C., Giliberto, L., Han, X., & D’Adamio, L. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01832-2 · Cited by 10 · see citing works
“This finding is consistent with observations reported in APOE2-carrying mice [82], but appears paradoxical given APOE2’s typical association with neuroprotection in AD [83, 84].”
ResultExploring the combined effects of sleep apnea and APOE-e4 on biomarkers of Alzheimer’s disease
Turner, A. D., Locklear, C. E., Oruru, D., Briggs, A., Bubu, O. M., & Seixas, A. A. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1017521 · Cited by 8 · see citing works
- Authors
- Conejero-Goldberg, C., Gomar, J. J., Bobes-Bascaran, T., Hyde, T. M., Kleinman, J. E., Herman, M. M., Chen, S., Davies, P., & Goldberg, T. E.
- Affiliations
- Northwell Health (US)
- Lieber Institute for Brain Development (US)
- National Institutes of Health (US)
- Corresponding author
- Goldberg, T E
- Venue
- Molecular Psychiatry
- Published
- 2014-02-04
- Volume
- 19
- Issue
- 11
- Pages
- 1243-1250
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2076631828
- Cited by
- 199
- References
- 55
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 16 · 2023: 10 · 2022: 15 · 2021: 25 · 2020: 50 · 2019: 12 · 2018: 14 · 2017: 19 · 2016: 8 · 2015: 7 · 2014: 1
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Drug Discovery Foundation
- F. Hoffmann-La Roche
- Northern California Institute for Research and Education
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, P30AG010129, K01AG030514)
- National Institute of Biomedical Imaging and Bioengineering
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- APOE2, Alzheimer's disease, neuroprotection, APOE isoforms, long-term potentiation, extracellular matrix, integrins, laminin, collagen, amyloid-beta clearance, mild cognitive impairment, biomarker signatures, excitotoxicity
- MeSH terms
- Adult, Aged, Alzheimer Disease, Cerebral Cortex, Collagen, Extracellular Matrix, Female, Humans, Laminin, Male, Middle Aged, Risk, RNA, Messenger, Biomarkers, Integrins, Long-Term Potentiation, Disease Progression, Protein Isoforms, Apolipoprotein E2, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
